Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial. Fusion is headquartered in Hamilton, ON, with offices in Boston, MA.
Looking for a particular Fusion Pharmaceuticals employee's phone or email?
The Fusion Pharmaceuticals annual revenue was $34.1 million in 2026.
Eric Burak is the Chief Technical Officer of Fusion Pharmaceuticals.
131 people are employed at Fusion Pharmaceuticals.
Fusion Pharmaceuticals is based in Hamilton, Ontario.
The NAICS codes for Fusion Pharmaceuticals are [3254, 325, 32541, 32].
The SIC codes for Fusion Pharmaceuticals are [28, 873, 87, 283].